Becton, Dickinson and Company
NYSE:BDXMedical - Instruments & Supplies
+$2.36 today
- Market cap
- $58.86B
- Beta
- 0.28
- P/E (TTM)
- 35.5
- EPS (TTM)
- $4.06
- Dividend yield
- 2.60%
Volume 1.32M
Average 2.76M
BDX EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
Becton, Dickinson and CompanyNYSE: BDX
EPS (Diluted) · Q4 FY2026 · quarter ended Sep 2026
EPS (Diluted) growth accelerates
Q4 FY2026 EPS (Diluted) of $2.54 rose 47.7% year over year, ahead of the -29.0% change in trailing-twelve-month EPS (Diluted). Sequentially, it rose 85.4% from the prior quarter. Over 3 fiscal years it compounded at -6.1% a year.
Context
- EPS (Diluted) increased in 1 of the last 3 fiscal years.
- FY2026 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 8 analysts of $13.25 (+224.1%) for the fiscal year ending Sep 2027, a step up from the -29.8% reported in FY2026.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $2.54+85.4% QoQ
- Last fiscal yearSep 2026
- $4.09-29.8% YoY
- LTMSep 2026
- $4.14-29.0% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2026
- 4.09 USD
- Year-over-year change
- -29.8%
- 4-year CAGR
- -8.7%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2026 | 2026-09-30 | 4.09 | -29.8% |
| FY2025 | 2025-09-30 | 5.83 | -0.5% |
| FY2024 | 2024-09-30 | 5.86 | +18.6% |
| FY2023 | 2023-09-30 | 4.94 | -16.0% |
| FY2022 | 2022-09-30 | 5.88 | — |
EPS (Diluted) vs competitors
How BDX compares with its peers on the latest reported figures
- BDX's LTM Sep 2026 EPS (Diluted) of $4.14 is the 3rd highest of the 11 companies compared; the peer median is $2.28.
- Its year-over-year change of -29.0% is the 8th highest of 11, against a peer median of +14.5%.
- Over three fiscal years its annual growth of -6.1% compares with a peer median of +1.4%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $8.19 | +277.4% | +4.5% | |
| LTM Jun 2026 | $7.82 | +17.1% | -4.2% | |
| LTM Sep 2026 | $4.14 | -29.0% | -6.1% | |
| LTM Jul 2026 | $4.06 | +11.8% | +9.8% | |
| LTM Sep 2026 | $2.7 | -66.2% | -1.6% | |
| LTM Sep 2026 | $2.66 | +36.4% | +18.2% | |
| LTM Mar 2026 | $1.9 | +113.9% | -25.3% | |
| LTM Jun 2026 | $1.18 | +177.6% | — | |
| LTM Mar 2026 | -$0.22 | +8.5% | — | |
| LTM Jun 2026 | -$2.04 | -579.8% | — | |
| LTM Jun 2026 | -$23.29 | -648.0% | — | |
| Peer median (excluding BDX) | $2.28 | +14.5% | +1.4% | |
Competitors are the stored peer set for BDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 | FY2026 Sep 2026 |
|---|---|---|---|---|---|
| Revenue | 18.87B | 19.37B | 20.18B | 21.84B | 19.46B |
| Cost of Revenue | 10.39B | 11.2B | 11.05B | 11.92B | 10.24B |
| Gross Profit | 8.48B | 8.17B | 9.13B | 9.92B | 9.21B |
| Gross Margin | 44.9% | 42.2% | 45.2% | 45.4% | 47.4% |
| Research & Development | 1.26B | 1.24B | 1.19B | 1.26B | 988M |
| Selling, General & Admin | 4.71B | 4.72B | 4.86B | 5.28B | 4.97B |
| Operating Expenses | 6.2B | 6.06B | 6.73B | 7.35B | 6.96B |
| Depreciation & Amortization | 2.23B | 2.29B | 2.29B | 2.46B | 2.24B |
| EBITDA | 4.41B | 4.4B | 4.82B | 4.96B | 4.61B |
| EBITDA Margin | 23.4% | 22.7% | 23.9% | 22.7% | 23.7% |
| Operating Income | 2.28B | 2.11B | 2.4B | 2.58B | 2.26B |
| Operating Margin | 12.1% | 10.9% | 11.9% | 11.8% | 11.6% |
| Interest Income | 16M | 49M | 163M | 38M | 27M |
| Interest Expense | 398M | 452M | 528M | 613M | 564M |
| Other Income / Expenses | (499M) | (449M) | (392M) | (696M) | (451M) |
| Income Before Tax | 1.78B | 1.66B | 2.01B | 1.88B | 1.81B |
| Pre-Tax Margin | 9.4% | 8.6% | 9.9% | 8.6% | 9.3% |
| Income Tax Expense | 148M | 132M | 300M | 204M | 388M |
| Net Income | 1.78B | 1.48B | 1.71B | 1.68B | 1.15B |
| Net Margin | 9.4% | 7.7% | 8.4% | 7.7% | 5.9% |
| EPS (Basic) | 5.93 | 4.97 | 5.88 | 5.84 | 4.11 |
| EPS (Diluted) | 5.88 | 4.94 | 5.86 | 5.83 | 4.09 |
| Weighted Avg Shares | 285.01M | 286.28M | 289.76M | 286.61M | 278.49M |
| Weighted Avg Shares (Diluted) | 287.36M | 288.39M | 291.01M | 287.12M | 279.94M |
Becton, Dickinson and Company
NYSE:BDX
Intrinsic Alpha fair value
Locked
Current Price
$216.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.